An update on options of therapy for aggressive mantle cell lymphoma

Ruan, Jia; Yamshon, Samuel; Besien, Koen van; Martin, Peter

doi:10.1080/10428194.2020.1755860

Search citation statements

Order By: Relevance

Paper Sections

Select...

Ibrutinib: First Generation Btk Inhibitor1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other clinical trials have assessed the efficacy of ibrutinib's combination with approved immunotherapeutics (reviewed in [41]). ORR as high as 88% (including 44% CR) was reported for R/R MCL patients treated with ibrutinib + rituximab [42].…”

Section: Ibrutinib: First Generation Btk Inhibitormentioning

confidence: 99%

Zanubrutinib: a novel therapeutic option for the treatment of B-cell neoplasms

et al. 2023

View full text Add to dashboard Cite

Bruton's tyrosine kinase (BTK) is a part of the B-cell receptor (BCR) signaling pathway.Activation of the BCR appears crucial for normal B cells as it regulates proliferation, differentiation, adhesion, survival, and apoptosis. Such signaling is also vital for malignant B cells, since many of them show constitutive activation of the BCR pathway. The development of ibrutinib, a best-in-class BTK inhibitor, has led to a new direction in the treatment of B-cell malignancies. Further studies have enabled the development of more potent and more selective BTK inhibitors, such as zanubrutinib. These novel agents were designed primarily to reduce adverse effects such as diarrhea, atrial fibrillation, rash, or hemorrhagic complications.Compelling data from clinical studies that have verified its efficacy and safety has allowed the approval of zanubrutinib in hematological malignancies such as mantle cell lymphoma, Waldenström's macroglobulinemia, chronic lymphocytic leukemia, and marginal zone lymphoma.

show abstract

Section: Ibrutinib: First Generation Btk Inhibitormentioning

confidence: 99%